Abstract Meta-analysis of interventions usually relies on randomized controlled trials. However, when the dominant source of information comes from single-arm studies, or when the results from randomized controlled trials lack generalization due to strict inclusion and exclusion criteria, it is vital to synthesize both sources of evidence. One challenge of synthesizing both sources is that single-arm studies are usually less reliable than randomized controlled trials due to selection bias and confounding factors. In this paper, we propose a Bayesian hierarchical framework for the purpose of bias reduction and efficiency gain. Under this framework, three methods are proposed: bivariate generalized linear mixed effects models, hierarchical power prior model and hierarchical commensurate prior model. Design difference and potential biases are considered in all models, within which the hierarchical power prior and hierarchical commensurate prior models further offer to downweight single-arm studies flexibly. The hierarchical commensurate prior model is recommended as the primary method for evidence synthesis because of its accuracy and robustness. We illustrate our methods by applying all models to two motivating datasets and evaluate their performance through simulation studies. We finish with a discussion of the advantages and limitations of our methods, as well as directions for future research in this area.
Introduction
Evidence synthesis is becoming increasingly important because of the explosive growth of evidence in the scientific literature and the need for timely and informed decisions in public health and medicine. 1 Meta-analysis, a systematic identification, appraisal, and statistical aggregation of all relevant evidence on a specified topic according to a predetermined and explicit method, 2 commonly constitutes the main statistical component of evidence synthesis.
Motivating data 2.1 Deep vein thrombosis data
Low molecular weight heparins (LMWH) is usually an indication for prophylaxis of deep vein thrombosis (DVT) in patients with severely restricted mobility after major orthopedic surgery. However, LMWH has been associated with the risk of serious or fatal hemorrhagic adverse events. In addition, the need for parenteral or subcutaneous administration is another disadvantage. In the past decade, research has focused on finding new active drugs that can be given orally and can improve the benefit and risk profile. In trials to develop new active drugs, the main objective is to demonstrate that these new drugs are non-inferior to LMWH in prophylaxis of DVT, which relies on a reasonable non-inferiority margin. To determine the margin, the treatment effect of LMWH compared with placebo has to be estimated as the first step. Thus we collected RCTs comparing LMWH versus placebo and single-arm studies of LMWH to facilitate the determination.
As is shown in Table 1 , this dataset includes 12 studies, 7 of which are RCTs comparing LMWH versus placebo and the remaining 5 are single-arm studies of LMWH. Let N represent the sample size (i.e. the number of patients assigned in each treatment arm), y represent the number of DVT events, and percentage represent the corresponding event probability. The author and year of publication for each study are also presented. Ignoring the five single-arm studies can lead to a substantial loss of information.
Advanced follicular lymphoma (FL) data
Many pharmaceutical companies are currently developing biosimilar products against the US-licensed product Rituxan (i.e. rituximab), which has oncology indications in patients with advanced follicular lymphoma (FL). Rituximab is usually used as an add-on therapy to cyclophosphamide, vincristine, and prednisone (CVP) in the advanced FL patient population. However, it is hard to achieve a reliable estimation on the treatment effect of rituximab as an add-on therapy due to the fact that there is only one RCT conducted since 1997 comparing rituximab þ CVP (R-CVP) versus CVP, and that all the other available evidence is from singe-arm studies of either R-CVP or CVP alone. Accordingly designing an equivalence trial to support the similarity or equivalence between the biosimilar product and rituximab is complicated. In this sense, rigorous methods that can combine both sources of evidence are essential and may help the regulatory agencies address their commitment to best practice for the conduct of meta-analysis.
We collected all available data through literature search from 1997, the year that rituximab was approved, up to 2014. Table 2 shows our assembled dataset of 12 studies including 1 RCT and 11 single-arm studies, to compare R-CVP versus CVP alone. The author and year for each study, the sample size N, the number of responses y, and the crude response probability are reported. In this example, as all studies but one are single-arm, it is evident that excluding these single-arm studies will hinder well-informed and comprehensive decisions.
Statistical methods
Without loss of generality, we consider a setting of meta-analysis of RCTs with two arms. The extension to multiple-arm RCTs will be discussed in section 3.4. Suppose there are totally M studies, n of which are RCTs comparing Treatments 1 and 2, m of which are single-arm studies containing only Treatment 1, and l of which are single-arm studies containing only Treatment 2. Note that M ¼ n þ m þ l. Let N 1i and y 1i denote the sample size and number of events for Treatment 1 in the i th study of the n RCTs, and let N 2i and y 2i denote these quantities for Treatment 2, where i ¼ 1, . . . , n. Let N 3i and y 3i represent the sample size and number of events for Treatment 1 in the ith study among the m single-arm studies, where i ¼ n þ 1, . . . , n þ m, and let N 4i and y 4i be the corresponding quantities for Treatment 2 in the ith study among the l single-arm studies, where
Further, let p 1i and p 2i denote the event probabilities for Treatments 1 and 2 in the n RCTs, let p 3i denote the event probability for Treatment 1 in the m single-arm studies, and let p 4i denote that for Treatment 2 in the l single-arm studies. We assume that the numbers of events in these ðm þ n þ l Þ studies follow independent binomial distributions as follows
Under equation (1), we propose three Bayesian hierarchical methods to model the event probabilities p 1i , p 2i , p 3i , and p 4i , and discuss their respective strengths and weaknesses in the following subsections.
Bivariate generalized linear mixed effects models
Bivariate generalized linear mixed effects models (BGLMMs) are proposed by adaptation of Zhang et al. 15 We start with BGLMM (I), formulated as
where 1 and 2 are the overall effects for Treatments 1 and 2, respectively; ð 1i , 2i Þ follows a bivariate normal distribution with a variance-covariance matrix AE ¼ accounting for the correlation between two treatment arms and heterogeneity across n RCTs; and 3i and 4i follow normal distributions accounting for the heterogeneities across the m and l single-arm studies, respectively. Here gðÞ is some proper link function. The probit link È À1 ðÞ is recommended because it enables a closed-form expression for the population-averaged treatment-specific event probabilities, i.e.
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È and are the cumulative distribution function and probability density function of the standard normal distribution. Then the marginal odds ratio (OR 21
and risk ratio (RR 21 ¼ 2 = 1 ) can be calculated correspondingly. 15 Since noninformative improper priors may lead to improper posteriors, we use their proper approximations, i.e. vague proper priors. Specifically, a N(0, 1000) prior is assigned to 1 and 2 , and an inverse-gamma prior IGð0:001, 0:001Þ is assigned to 
We call this model naive pooling (NP) (I). This model assumes that all available information is from single-arm studies, synthesizes information for two treatment arms separately, and as such ''breaks randomization''. Another simplification is
We name it NP (II). In this model, missing entries are imputed automatically with Markov chain Monte Carlo (MCMC) algorithm and the correlation between two arms is incorporated as well. Note that neither the design difference between the two study types nor the potential biases from single-arm studies are considered in naive pooling models.
Hierarchical power prior model
Power priors, introduced by Ibrahim and Chen, 28 offer a simple way to incorporate and downweight historical data by raising the historical likelihood to a power 0 2 ½0, 1 and re-standardizing the result to a proper distribution. Along the lines of this work, we can raise the likelihoods of the m and l single-arm studies to powers 01 2 ½0, 1 and 02 2 ½0, 1, respectively, and specify priors on 01 and 02 , to incorporate and downweight information.
Based upon the BGLMM (I), we build up the model as follows. For simplicity of notation, we let h denote the parameters of interest in the BGLMM (I), i.e. h ¼ ð 1 , 2 , AE, 3 , 4 Þ, and let a 0 denote the power parameters, i.e. a 0 ¼ ð 01 , 02 Þ.
Let
, . . . , y 3,nþm Þ, and y 4 ¼ ð y 4,nþmþ1 , . . . , y 4,nþmþl Þ. Then the joint prior for (h, a 0 ) is as follows Note that by specifying a prior for a 0 rather than directly assigning specific numerical values to a 0 , we allow more flexibility in weighting single-arm studies. 28 However, it has a tendency to downweight the single-arm studies overmuch, therefore we use a Beta(10, 1) prior. This prior distribution has a mean value of 0.91 and a 95% CI from 0.69 to 0.99 indicating a priori that there is moderate to strong similarity between single-arm studies and RCTs, which is the underlying reason for synthesizing the two types of studies. Here a truncated gamma prior or a truncated normal prior can also work well as they have similar theoretical, computational and practical properties as a beta prior. More prior specifications for the power parameters have been discussed in several papers. [29] [30] [31] Gamalo et al. 32 further proposed an ''order restricted power prior,'' which incorporated dependence of the powers but was more suitable when combining information from multiple historical studies.
Finally the joint posterior distribution for (h, a 0 ) is proportional to
Þ are the likelihood functions specified in the BGLMM (I) for the n RCTs, and m and l single-arm studies, respectively. We refer to model (5) as the hierarchical power prior (HPP) model.
The HPP model allows us to downweight single-arm studies through power parameters defined on the interval ½0, 1, but it does not directly parameterize the agreement of information from the two types of studies. In addition, the HPP tends to over-attenuate the impact of the single-arm studies and thus needs fairly large power parameters to ensure sufficient borrowing.
Hierarchical commensurate prior model
As a solution to the problems in the HPP model, we propose a hierarchical commensurate prior (HCP) model to offer further flexibility in downweighting single-arm studies and to enable the measurement of commensurability, i.e. the degree to which the two sources of information are commensurate with. The core idea of this method is based on a work by Hobbs et al. 33 We assume different mean treatment effect parameters for the two types of studies (i.e. 1 and 2 for RCTs and 3 and 4 for single-arm studies). This dichotomous parameterization allows us to measure the degrees of commensurability between 1 and 3 and between 2 and 4 . More specifically, we let 1 and 2 follow normal distributions with means 3 and 4 and precisions 1 and 2 , where 1 and 2 parameterize commensurability. Now the joint commensurate prior is formulated as follow
where h ¼ ð 1 , 2 , AE, 3 , 4 Þ and 0 ðhÞ represent the initial priors. Vague priors are assigned again, namely a N(0, 1000) prior to 3 and 4 and a Gammað0:01, 0:01Þ prior to 1 and 2 . Note that other prior specifications of 1 and 2 can also be adopted here; for example, a ''spike and slab'' distribution. 33, 34 Larger values of 1 and 2 indicate increased commensurability and induce increased borrowing of strength from the single-arm data. Specifically, if 1 and 2 approach zero, then ðh, 1 , 2 Þ approaches 0 ðhÞ, effectively ignoring the single-arm studies; if 1 and 2 approach infinity, then ðh, 1 , 2 Þ approaches
4 ÞÂ 0 ðhÞ, equivalent to pooling the RCTs and single-arm studies together without downweighting.
The joint posterior distribution is formulated as
where
The HCP model offers more flexibility in downweighting single-arm studies according to the degree of commensurability between single-arm studies and RCTs. The more commensurate the two sources of information are, the more information the HCP model borrows from the single-arm studies.
The Deviance Information Criterion (DIC) 35 and residual deviance D res 36 are reported. The DIC is defined by DðÞ þ p D , where DðÞ ¼ E jData ½DðÞ is the posterior expectation of the deviance, and p D ¼ DðÞ À Dð " Þ is the effective number of model parameters. Here " refers to the posterior expectation of , i.e. E j y ðÞ. DIC rewards better fitting models through DðÞ and penalizes more complex models through p D . D res is defined as the posterior mean of the deviance under the current model, minus the deviance for the saturated model. All models can be implemented via MCMC methods using the WinBUGS software. 37 A generous burn-in period of 500,000 iterations was used, with 500,000 subsequent iterations retained for posterior treatment effect estimates. Two parallel chains were generated using different initial values. The convergence of Markov chain Monte Carlo (MCMC) chains can be assessed by visual inspection of the chains and by the Gelman-Rubin convergence statistic. 38 
Extension to settings with more than two treatments
In previous subsections, we have focused on comparisons of two treatments. The proposed methods can be adapted to cases where simultaneous comparisons of multiple treatments are of interest. There are two types of scenarios: (1) when we have multiple-arm RCTs; and (2) when we want to compare multiple treatments but no trial has simultaneously compared them. Multiple-arm RCTs are usually conducted, for instance, when two different doses of Treatment A are compared with control B or when Treatment A is compared with previous gold-standard Treatment B and control C. This seems to be the natural outgrowth of our methods and does not require additional modeling skills. For the second scenario, ''network meta-analysis'' 15, 16, 18, 39, 40 can be applied which combines evidence from both direct comparisons of treatments within RCTs and indirect comparisons across trials through a common comparator. This technique is increasingly popular recently in evidence-based medicine and comparative effectiveness research. To apply this technique, inconsistency between direct and indirect comparisons needs special attention in addition to heterogeneity between designs. Our proposed models will also need to be tailored and refined. Finally, our Bayesian framework eases the inferential burden for both scenarios where large covariance matrices are usually involved. In contrast, frequentist inference may encounter convergence problems because the (restricted) maximum likelihood estimate of the between-study correlation is often at or very close to boundary of its parameter space and thus the estimated covariance matrix is singular. 41, 42 
Data analysis
In this section, we apply the statistical methods proposed in previous section to the motivating datasets introduced in Section 2 and compare the results. In the first example, the dataset contains multiple RCTs and multiple singlearm studies; whereas in the second example, all studies but one are single-arm.
DVT data
In this dataset, the primary outcome is the occurrence of DVT event, thus a lower event probability implies a better treatment. Table 3 presents the synthesis results from the proposed models of the 12 studies comparing LMWH versus placebo. Here 1 and 2 denote the population-averaged DVT event probabilities for LMWH and placebo, respectively. OR 21 , RD 21 and RR 21 show the relative treatment effect of placebo versus LMWH. In Table 3 Note that though there are marginal differences in magnitude of the estimated values, all models concur that LMWH is statistically significantly more efficacious than placebo in the prevention of DVT.
Though the BGLMM (I) shows a better fit with D res ¼ 18:27, the DIC values from the BGLMM (I) and HCP models are comparable (123.76 and 123.83, respectively), implying similar goodness of fit after penalizing model complexity. In addition, the two DIC values are smaller than those from the other models. We choose the HCP as our final model because it is the most flexible model in terms of downweighting information from single-arm studies. We now present the results from the HCP model. Patients taking placebo have a higher populationaveraged DTV event probability (0.50; 95% CI ¼ 0.34 to 0.67) than patients taking LMWH (0.19; 95% CI ¼ 0.11 to 0.31). The OR 21 , RD 21 and RR 21 are 4.33 (95% CI ¼ 1.92 to 9.96), 0.31 (95% CI ¼ 0.14 to 0.48) and 2.65 (95% CI ¼ 1.54 to 4.54), respectively. Note that the DIC value from the BGLMM (II) is calculated based solely on the data from RCTs, thus it is not presented in Table 3 .
To visually compare different models, Figure 1 depicts the posterior medians and 95% CIs of all parameters. We observe that none of the 95% CIs of RD 21 from these six models intersect the dashed line x ¼ 0, and none of the 95% CIs of OR 21 and RR 21 intersect the dashed line x ¼ 1, indicating statistically significant results from all the models. We also observe that the lengths of the intervals from the HPP and HCP modes are comparable to those from the other models, thus these two models do not lose much efficiency when available information are sufficient though they have more parameters to estimate.
Prior sensitivity analysis is conducted for the HPP and HCP models with the results presented in Table 4 . We start with the HCP model. The first four investigate the sensitivity of 1 and 2 to more informative normal distributions, namely N(0, 100) and N(0, 10), and heavy-tailed t-distributions with degrees of freedom 2 and 5. The estimated 1 and 2 are all close to those from the HCP in Table 3 , thus the HCP model is robust to these other prior distributions. The following four explore the sensitivity of commensurate parameter to more and less informative Gamma priors including Gamma(0.1, 0.1), Gamma(0.001, 0.001), Gamma(1, 0.5) and Gamma(3, 1). It seems that the HCP is not particularly sensitive to these prior distributions either. Next, Wishart priors WðI 2 , 2Þ and WðR À1 , 2Þ with R being a 2 Â 2 matrix with diagonal elements equal to 0.1 and off-diagonal elements equal to 0.005 are used to assess the sensitivity of the precision matrix AE À1 . Comparison of Tables 3 and 4 suggests that more informative Wishart priors for AE À1 do not have substantial effect on the estimates. Finally, prior sensitivity analysis for 0 in the HPP is conducted using Beta(5, 1), Beta(3, 2), Beta(1, 1), Beta(2, 2) and Beta(2, 5) as priors and they all yield similar results.
Advanced FL data
We now present the synthesis results for the advanced FL dataset in Table 5 . Here 1 and 2 denote the estimates of the population-averaged response probabilities for CVP and R-CVP, respectively. They are 0. 64 In terms of relative summaries, the NPs (I) and (II) produce statistically significant results and suggest that R-CVP is better than CVP alone. For example, for NP (I), OR 21 has a posterior median 3.25 with a 95% CI ð1:81, 6:05Þ; RD 21 has a posterior median 0.21 with a 95% CI ð0:10, 0:35Þ; and RR 21 has a posterior median 1.33 with a 95% CI ð1:13, 1:70Þ. However, the BGLMM (I), BGLMM (II), HPP, and HCP do not show statistically significant results in the comparison of R-CVP versus CVP; namely, the 95% CIs for OR 21 and RR 21 from these models cover 1 and those for RD 21 Table 5 . Under the BGLMM (I), BGLMM (II), HPP and HCP models, the 95% CIs for RD 21 pass through the dashed line x ¼ 0, and those for OR 21 and RR 21 pass through the dashed line x ¼ 1. However, under the NPs (I) and (II), the 95% CIs for RD 21 and those for OR 21 and RR 21 do not intersect the lines x ¼ 0 and x ¼ 1, respectively. This conflict may be due to possible over-parameterization of the BGLMM (I), BGLMM (II), HPP and HCP models under this extremely sparse dataset which contains only 1 RCT. Accordingly, there may have been insufficient power making inference from these models. If, however, we had multiple RCTs as in the DVT dataset, these models would make perfect sense and were expected to outperform the NPs (I) and (II). We also observe that the HPP and HCP models obtain wider 95% CIs, which we believe is again due to the fact that the data are very sparse whereas the two models have additional parameters to estimate (i.e. 01 and 02 in the HPP model, and 1 and 2 in the HCP model).
Simulations
In this section, we evaluate the performance of the proposed models via simulations under various scenarios. Relative biases (i.e. biases / true values) and coverage probabilities of the 95% CI are used to compare point and interval estimates from these models. One thousand replicates of simulations are conducted for all scenarios.
Simulation setting

Simulation 1
We generate a pool of evidence comprising 30 studies to compare two treatments under five scenarios. Figure 3 shows the data structures under these five scenarios labeled as S1-S5. In S1, n ¼ 15, m ¼ 10, and l ¼ 5; in S2, The five scenarios enable us to evaluate our methods under both balanced (i.e. S2) and unbalanced cases (i.e. S1, 3, 4, and 5). For the unbalanced case, we investigate both the case where majority of studies are RCTs (i.e. S1) and the case where majority of studies are single-arm studies (i.e. S3-5), which simulate the motivating data sets. For RCTs, event probabilities p 1i and p 2i in Trial i are generated according to Èð
, where i ¼ 1, . . . , n. For single-arm studies of Treatment 1, event probabilities are generated according to Èð
Þ, where i ¼ n þ 1, . . . , n þ m; for single-arm studies of Treatment 2, event probabilities are generated through Èð
Note that 0.2 and 0.4 represent the systematic differences between the single-arm studies and RCTs for Treatments 1 and 2, respectively. For simplicity we assign 100 participants to each treatment arm within each trial. Then the numbers of events are generated according to y 1i $ Binð100, p 1i Þ and y 2i $ Binð100, p 2i Þ with i ¼ 1, . . . , n þ m þ l. We let 1 
Simulation 2
In order to explore whether the proposed models are robust when there are larger heterogeneity between the two types of studies and when the study sample sizes vary across the two types of studies, we conduct additional simulations under six scenarios. For all scenarios, we let n ¼ m ¼ l ¼ 10 as in S2 and thus label them S2.1-S2.6. For S2.1 and S2.2, the systematic differences between RCTs and single-arm studies remain 0.2 and 0.4; for S2.3 and S2.4, they are set to be larger values of 0.4 and 0.6; for S2.5 and S2.6, they have even larger values of 0.6 and 0.8. In S2.1, S2.3, and S2.5, 200 participants are assigned to RCTs and 80 are assigned to single-arm studies; in S2.2, S2.4, and S2.6, 250 participants are assigned to RCTs and 60 of them are assigned to single-arm studies. Basic parameters including 1 , 2 , 1 , 2 , , 3 and 4 are set to be the same values as in Simulation 1. Then y 1i and y 2i are generated in the same way. 
Simulation results
Simulation 1
The NPs (I) and (II), BGLMM (I), HPP, and HCP are fitted to the simulated datasets under the five scenarios described in Section 5.1 (note that BGLMM (II) is not explored in simulations because its prior specification for 1 and 2 relies on a separate analysis of single-arm studies). We also synthesize the information from only RCTs through gð p 1i Þ ¼ 1 þ 1i , gð p 2i Þ ¼ 2 þ 2i , with ð 1i , 2i Þ $ Nð0, AEÞ, under Scenarios 1-4 (note that Scenario 5 contains only 1 RCT and thus is not suitable here). The synthesis results of solely RCTs are denoted by RCTs Ã in Table 6 and compared with those from the proposed methods.
Let us first compare the point estimates and interval lengths based on the data of solely RCTs with those based on both RCTs and single-arm studies. As is shown in Table 6 , the estimates of 1 and 2 from the RCTs Ã are closer to those from the HPP and HCP models than those from the NP (I), NP (II) and BGLMM (I), under all scenarios. In other words, the HPP and HCP models downweight the single-arm studies to a larger degree than the other models. Posterior credible interval lengths of 1 and 2 from all proposed models (except some 2 under the NP (II)) are shorter than those from the RCTs Ã . It suggests that the proposed methods do gain precision by including single-arm studies in synthesis. Note that the exception of NP (II) is understandable because it hypothetically assumes the single-arm studies to be two-arm with one arm missing and imputes these missing data. Now let us compare the performance of the proposed models. Table 6 presents the relative biases of 1 and 2 and coverage probabilities of their 95% CIs from the proposed models under the five scenarios. Note that the MSEs of 1 and 2 are not presented here because they are consistently very small (at 3 decimal points) under all scenarios for all models. The relative biases are larger from the NP (I), NP (II) and BGLMM (I) than those from the HPP and HCP under Scenarios 1-4. Under Scenario 5, the relative biases from the BGLMM (I) and HCP are smaller than those from the other models. In short, the HCP seems to be the best model in terms of relative bias throughout all simulation scenarios.
Considering the observed coverage probabilities at the nominal level of 0.95, the NP (I), HPP and HCP give close to the nominal coverage under Scenarios 1 and 2, while the NP (II) and BGLMM (I) produce coverage probabilities a little further from the nominal level. With the number of RCTs becomes smaller and smaller from Scenarios 3 to 5 (i.e. we have less and less information for estimation), the HPP and HCP lose precision dramatically yielding coverage probabilities that are too high. This phenomenon is particularly evident under Scenario 5 with the coverage probabilities under these two models nearly 100%, which is consistent with what we have observed in the real data analysis of the advanced FL dataset. Although the NP (I), NP (II) and BGLMM (I) also produce unsatisfactory coverage probabilities under Scenarios 3-5 (more specifically, lower than the nominal level), they are not as extreme as those from the HPP and HCP. Therefore sparse data should be handled more carefully. Figure 4 further compares the performance of different models across scenarios to augment Table 6 . The relative biases for 1 and 2 are shown in panel A of Figure 4 , and coverage probabilities are shown in panel B. The x-axis lists the five scenarios. In panel A, the relative biases from each model under different scenarios are labeled by points and connected through lines. Looking at the trend of each line, relative biases tend to become larger going from Scenarios 1 to 5; in other words, more sparse information may yield more biased estimation.
Comparison across different models shows that the relative biases from the HCP for both 1 and 2 are closer to 0 than the other models, under all scenarios. Thus we draw a conclusion that the HCP offers the most accurate estimation among all models. In panel B, the coverage probabilities from each model under different scenarios are labeled by points and connected through lines. The trend of each line also reveals that sparse information can lead to unsatisfactory coverage probability, especially for the HPP and HCP models under Scenario 5, where the coverage probabilities are nearly 100%. Figure 5 summarizes the results of Simulation 2. Panel A shows the relative biases for 1 and 2 and panel B shows the coverage probabilities. Let us first look at the relative bias for 1 displayed on the left side of panel A. The comparison across models shows that the NP (I), NP (II) and BGLMM (I) produce more biased estimates than the HPP and HCP models under all scenarios. The HPP performs similarly to the HCP under S2.1-S2.4, but is inferior to the HCP under S2.5-S2.6. In short, the HCP produces the most accurate estimates. All lines except the one for the HCP show an upward trend along the increasing heterogeneity between RCTs and single-arm studies. The NP (I), NP (II) and BGLMM (I) produce dramatically larger biases when the heterogeneity becomes lager. Take NP (II) as an example, the relative bias is around 0.05 under S2.1 and S2.2, around 0.10 under S2.3 and S2.4, and 0.15 under S2.5 and S2.6. The HPP also shows an ascending trend but not as sharply as the aforementioned three models. The performance of the HCP seems stable across different scenarios, suggesting its robustness to larger heterogeneity between RCTs and single-arm studies. Another phenomenon we observed is that the relative biases are about the same for S2.1 and S2.2, as well as for S2.3 and S2.4, and for S2.5 and S2.6. Thus the performance of the models is not affected by heterogeneous study sample sizes between the two types of studies. We observe similar pattern for 2 on the right side of panel A.
Simulation 2
In terms of coverage probability for 1 , all models except NP (II) broadly achieve the 95% nominal level under S2.1 and S2.2. The coverage probabilities from the NP (I), NP (II) and BGLMM (I) drop sharply along with the increase of heterogeneity between RCTs and single-arm studies. The HPP model performs generally well across all scenarios except under S2.5 and S2.6 where the coverage probabilities are only around 0.90. The HCP performs well under all scenarios. For 2 , all models work well under S2.1 and S2.2. From S2.3 to S2.6, the coverage probabilities from the HPP and HCP continue achieving the nominal level, while those from the NP (I), NP (II) and BGLMM (I) drop sharply.
Discussion
For many biomedical research areas, such as interventional cardiology, orphan diseases, and rare cancer trials, a vast of information may be available from single-arms studies, while there may be only limited number of RCTs. It is important to synthesize single-arm studies and RCTs in order to improve statistical efficiency on the relative effectiveness of treatment options and to better inform decision-making process. However, few methods have synthesized these two sources of information. In this paper, we proposed a Bayesian framework with three methods to flexibly combine these two sources of evidence with the advantage of improved precision compared to traditional synthesis of RCTs only.
The proposed methods were evaluated empirically through two real data analyses and extensive simulations. In summary, the NPs (I) and (II) make a strong assumption of no difference between study designs thus are not recommended to synthesize RCTs and single-arm studies. However, when available information from RCTs is extremely sparse, as is shown in the advanced FL data set and in Scenario 5 of simulations, these two models may provide inferior yet reasonable alternatives. On the other hand, the BGLMM (I), BGLMM (II), HPP and HCP models account for design difference between single-arm and two-am trials and adjust for potential bias from single-arm studies. Both the HPP and HCP models provide ways to downweight the single-arm studies and automate the prior elicitation procedures. Furthermore, the HCP model offers a way to measure commensurability between information from RCTs and single-arm studies and downweight single-arm studies accordingly. Typically, an adequate number of studies in meta-analysis is needed to ensure identifiability, sufficient precision and a reasonable power, especially for complex models. In general, the HCP offers more flexibility to integrate information of different qualities or from different designs, and thus is recommended as the primary method.
Criticisms can be made. Many researchers dislike the AB framework, arguing that the assumption of exchangeable absolute treatment effects ''breaks randomization''. 20 We admit that it may be stronger than the assumption of exchangeable treatment contrasts in the CB framework. However, as Senn 43 discussed, little harm is likely to be done in practice with this stronger assumption. In addition, the assumption of exchangeable event rates or studies is reasonable in most conditions, presented in highly cited papers including Van Houwelingen et al. 44 and Shuster et al. 45 In meta-analysis, randomized studies are usually collected and screened with predetermined inclusion and exclusion criteria that are primarily concerned with characteristics of the target population. A (usually contrast-based) meta-analysis is then conducted under the fundamental assumption that relative treatment effects are exchangeable across studies. However, this assumption would be flawed if the collected studies were heterogeneous, and thus did not represent a common target population. For example, if a study drug performs better on younger or healthier people, the exchangeability of relative effects may not hold. In contrast, exchangeability of event rates may be a fair assumption to make, given that the meta-analysis data often arise from broadly similar study populations.
Hong et al. 21 instead talked about advantages of the AB framework over the CB framework. First, the AB framework estimates absolute effects based on which any relative effects on any scale can be inferred, whereas the CB framework requires a proper selection of scale, which is difficult and empirically unverifiable. Second, the AB framework can provide more useful and straightforward interpretations when individual-patient data are available. Third, in hierarchical Bayesian theory, methods and computing, correlations in all data sources should be modeled, which is what the AB framework does by incorporating correlations among all treatment arms. In contrast, the CB framework requires additional assumptions or external information to capture and estimate the unknown within-study correlations.
One limitation of our methods is that we only considered single-arm studies in addition to RCTs in the synthesis process though we may have access to pseudo-RCTs and observational studies which may contain additional information and are worthy of consideration as well. Moreover, our methods only consider the comparison of two interventions, but usually multiple treatments are available for a particular disease and thus their simultaneous comparisons are of interest to patients, clinicians, and decision-makers. Tapping into and utilizing the data abundance of current era would enhance the power of evidence synthesis and facilitate better informed decisions. Our future endeavor will focus on more generalized evidence synthesis and more complex data structures involving various designs and multiple treatments.
Future work also includes reducing the lag between knowledge generation and implementation. First, concerns on additional heterogeneity from different designs, differential publication selection processes for different types of studies (i.e. differential publication biases issue), and inconsistency between direct and indirect evidence may hinder the application and popularization of more generalized evidence synthesis. Therefore, reliable measures to detect these issues and robust approaches to address them are essential and await exploration. Second, most of the current available R packages on meta-analysis are focused on single study type, 46 thus work remains to be done in developing user-friendly software for meta-analysis synthesizing various types of studies.
